Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 14, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2023-11-06
DOI
10.3389/fneur.2023.1277477
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
- (2023) Stephanie Meier et al. JAMA Neurology
- Current and Future Biomarkers in Multiple Sclerosis
- (2022) Jennifer Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
- (2022) Pascal Benkert et al. LANCET NEUROLOGY
- Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
- (2022) Tjalf Ziemssen et al. Frontiers in Immunology
- Changes in prognosis of the Danish multiple sclerosis population over time
- (2022) Melinda Magyari et al. Multiple Sclerosis Journal
- Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
- (2022) Emilio Portaccio et al. JAMA Neurology
- The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades1
- (2022) Lucía Romero-Pinel et al. Multiple Sclerosis and Related Disorders
- Serum neurofilament‐light and glial fibrillary acidic protein levels in hydroxychloroquine‐treated primary progressive multiple sclerosis
- (2022) Carlos Camara‐Lemarroy et al. EUROPEAN JOURNAL OF NEUROLOGY
- Ageing and multiple sclerosis
- (2022) Jennifer S Graves et al. LANCET NEUROLOGY
- Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4
- (2022) Christoph Kessler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Diagnosis and Treatment of Multiple Sclerosis
- (2021) Marisa P. McGinley et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation
- (2021) Frank Dahlke et al. Multiple Sclerosis Journal
- Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups
- (2021) Gloria Donninelli et al. Frontiers in Immunology
- Clinical and radiological activity of secondary progressive multiple sclerosis in a population‐based cohort
- (2021) Guillaume Mathey et al. EUROPEAN JOURNAL OF NEUROLOGY
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)
- (2021) Francisco Pérez-Miralles et al. Multiple Sclerosis and Related Disorders
- Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum
- (2021) Marcus W. Koch et al. NEUROLOGY
- Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools
- (2021) Svenja Klinsing et al. EUROPEAN JOURNAL OF NEUROLOGY
- The 2013 clinical course descriptors for multiple sclerosis
- (2020) Fred D. Lublin et al. NEUROLOGY
- The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history
- (2020) Per Soelberg Sorensen et al. BRAIN
- A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis
- (2020) Gavin Giovannoni et al. NEUROLOGY
- Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity
- (2020) Xavier Ayrignac et al. Scientific Reports
- Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis
- (2020) Panayiota Petrou et al. BRAIN
- Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
- (2020) Eva Fernandez‐Diaz et al. Annals of Clinical and Translational Neurology
- Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
- (2019) Hans Lassmann Frontiers in Immunology
- Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades
- (2019) Omid Beiki et al. JAMA Neurology
- Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
- (2019) Jens Kuhle et al. NEUROLOGY
- Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience
- (2019) Chiara Zecca et al. Multiple Sclerosis Journal
- Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study
- (2019) Abdorreza Naser Moghadasi et al. Multiple Sclerosis and Related Disorders
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Progressive Forms of Multiple Sclerosis
- (2018) Burcu Zeydan et al. NEUROLOGIC CLINICS
- Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials
- (2018) Richard S Nicholas et al. Multiple Sclerosis Journal
- Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
- (2018) Jordana Hughes et al. JAMA Neurology
- Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
- (2018) J. Lorscheider et al. EUROPEAN JOURNAL OF NEUROLOGY
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study
- (2016) Helga Westerlind et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study
- (2016) Helga Westerlind et al. Multiple Sclerosis Journal
- Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis
- (2015) Rikke Ratzer et al. Multiple Sclerosis Journal
- Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review
- (2015) T. Ziemssen et al. PLoS One
- Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis
- (2015) Rikke Ratzer et al. Multiple Sclerosis Journal
- TheVGAMPackage for Categorical Data Analysis
- (2015) Thomas W. Yee Journal of Statistical Software
- Modelling the natural history of primary progressive multiple sclerosis
- (2014) Katharine E Harding et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Relapses and disability accumulation in progressive multiple sclerosis
- (2014) M. M. Paz Soldan et al. NEUROLOGY
- Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
- (2014) J. Romme Christensen et al. NEUROLOGY
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Cortical lesion load associates with progression of disability in multiple sclerosis
- (2012) M. Calabrese et al. BRAIN
- The changing face of multiple sclerosis clinical trial populations
- (2011) Bernard M.J. Uitdehaag et al. CURRENT MEDICAL RESEARCH AND OPINION
- Lesion enhancement diminishes with time in primary progressive multiple sclerosis
- (2010) Z. Khaleeli et al. Multiple Sclerosis Journal
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study
- (2008) Zhaleh Khaleeli et al. ANNALS OF NEUROLOGY
- Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years
- (2008) Edmar A.S. de Araújo et al. ARQUIVOS DE NEURO-PSIQUIATRIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started